The positive interim data from the Phase 1 trial of PORT-2 (IMM60) indicates early evidence of single agent activity with a reduction of several target lesions. This news is directly related to Portage Biotech's core product and has a high relevance to the company's stock price. The encouraging safety and tolerability data, along with the company's plans to expand the trial, signal potential future success for the product, which could positively impact the stock price in the short term.